NIH Just Told Mentored Investigators They Cannot Run a Trial. 573 Active K23s Sit on the Wrong Side of the Line.

On August 12, 2026, NIH published NOT-OD-26-098, a notice titled, blandly, "Notice of NIH Updates to Career Development (K) Award Programs." Three of its four provisions are genuine housekeeping: consolidating a sprawl of individual K notices of funding opportunity into parent NOFOs organized by program type, dropping the Data Management and Sharing Plan requirement from K applications, and clarifying allowable uses of K funds.

The fourth provision is not housekeeping. Beginning with due dates on or after October 12, 2027, K award funds may no longer support conducting a clinical trial, a clinical trial feasibility study, or an ancillary study to an existing clinical trial. NIH is simultaneously retiring the entire family of "Independent Clinical Trial Required" K NOFOs, which expire July 13, 2027.

For a large share of the clinical research workforce, that single sentence redraws the path to independence.

The number that makes this concrete

The mechanism most exposed is the K23, the Mentored Patient-Oriented Research Career Development Award — the standard vehicle for a clinically trained investigator building a patient-facing research career.

An analysis of NIH RePORTER data by Julie Locher, Professor Emerita at the University of Alabama at Birmingham, found 573 active K23 awards funded through Clinical Trial Required announcements — roughly 46% of all active K23s. Nearly half the K23 portfolio was built on the exact activity the new policy prohibits.

The K08 (Mentored Clinical Scientist Research Career Development Award) and portions of the K01 portfolio sit in the same blast radius wherever a trial was the centerpiece of the mentored research plan. Reporting on the change also indicates the restriction extends to F32 postdoctoral fellowships, which already carried similar limits.

Why "just do it under your mentor's trial" is not the same thing

NIH's implicit answer is that K awardees can still gain trial experience by participating in trials led by their mentors. That preserves exposure. It does not preserve the thing a K award exists to produce.

The traditional arc in patient-oriented research runs: formative research → intervention development and refinement → a pilot or feasibility trial the candidate leads → an independent R-level trial. The pilot is the hinge. It is where a candidate demonstrates they can hold a protocol, an IRB, a DSMB, a recruitment pipeline, and a budget at the same time — the evidence a study section needs to believe a first R01 trial is a reasonable bet.

Under the new policy, a K awardee may sit on a mentor's trial team but cannot lead one, even a small pilot, without securing separate funding.

Locher raised three objections that are hard to dismiss. First, how does an investigator develop independence conducting randomized controlled trials without ever leading one during the career development stage? Second, a K that cannot support a trial now closely resembles an F32 fellowship, collapsing the developmental distinction between the postdoctoral and mentored-faculty stages. Third — and this is the strategic point — investigators at institutions without a deep bench of mentor-led trials or discretionary institutional pilot funds are materially worse off than peers at large research-intensive centers. Locher's framing is that the policy may "unintentionally advantage investigators at large research-intensive institutions."

Theodore "Jack" Iwashyna, an ICU physician at Johns Hopkins, put the methodological objection more sharply, criticizing a posture in which "their definition of 'gold standard RCT' is 'no RCT at all.'"

The conversion data cuts against the change

The strongest empirical argument against the policy comes from Jeremy Berg, former director of NIGMS. His analysis of K awardees from 2010 to 2020 found that roughly 23% of K clinical trial awardees later received an R01 to conduct a clinical trial — more than twice the rate seen among K awardees whose projects did not involve trials.

That is the metric NIH normally uses to defend career development spending: does the award convert into independent research funding? On that measure, the clinical trial K was outperforming, not underperforming.

There is a demographic dimension as well. Roughly two-thirds of recipients of K clinical trial awards were women, and the funded work concentrated in HIV, women's health, and behavioral research — areas where mentored pilot trials are often the only viable route to an evidence base.

The replacement does not exist yet

This is the part practitioners should register most clearly: NIH has not announced a replacement mechanism. It has announced an intention to build one.

Alongside NOT-OD-26-098, NIH issued NOT-OD-26-095, a Request for Information seeking input on funding models that would let a mentored K awardee serve as principal investigator of a clinical trial supported through a mechanism separate from the K award — the K covering salary, mentorship, and protected time; a companion award covering the trial itself.

Responses are due September 30, 2026. Any stakeholder may respond: investigators, institutions, professional societies, patient advocacy organizations, industry, and members of the public.

Jenna Norton, an NIH program director, named the sequencing problem directly: "Making changes before a new plan is in place is disruptive."

That is the operative risk. The prohibition has a firm date. The replacement has an RFI.

What this changes about how you plan

If you are preparing a K application now, you have three real cycles under the old rules. K new applications are due February 12, June 12, and October 12; resubmissions March 12, July 12, and November 12. The Clinical Trial Required NOFOs expire July 13, 2027, and the funding restriction attaches to due dates on or after October 12, 2027. The February 12 and June 12, 2027 dates are your last clean windows for a trial-centered K. Treat June 12, 2027 as the hard wall and build backward from it, leaving room for one resubmission before the door closes.

If your K is already active, you are not retroactively affected — the policy attaches to future due dates. But if you were counting on a competing extension, a supplement, or a follow-on K to carry the trial phase, re-plan now.

If you are drafting for late 2027 and beyond, restructure the research plan rather than disguise it. A career development plan built on assay development, cohort construction, secondary analysis of existing trial data, measure validation, implementation science, or mechanistic work remains fully fundable and does not require the prohibited activity. What will not survive review is a trial in everything but name.

Pair the K with a separate trial award. This is the shape NIH is signaling it wants and the shape NOT-OD-26-095 is exploring. Realistically that means an R21, R34 planning grant, foundation trial funding, institutional CTSA pilot dollars, or a departmental award running in parallel with the K. Start those conversations with your CTSA hub and department chair a year earlier than you otherwise would — the K timeline no longer carries the trial timeline with it.

Respond to the RFI. A September 30 deadline on a question this consequential, in a year when NIH has been unusually responsive to comment volume, is not a formality. Specificity helps: describe the trial you would have run, its budget, and what its absence costs your trajectory.

The larger pattern

NOT-OD-26-098 is not an isolated action. It lands inside a year of structural change at NIH: the funding opportunity portfolio cut from over 800 NOFOs to under 500, continuous submission eliminated as of August 10, 2026 with late-application eligibility narrowed to a two-week window and revoked outright for fellowships and SBIR/STTR, a reworked Data Management and Sharing Plan format, and an RFI on withholding impact scores and percentiles from applicants.

Each is defensible on simplification grounds. Taken together, they compress the number of ways into NIH funding and reduce the informational and scheduling slack applicants have relied on. K awards, notably, also retain their five legacy review criteria — Candidate, Career Development Plan, Research Plan, Mentor(s), and Environment — because the Simplified Review Framework never applied to them. The mechanism is being narrowed in scope while its review architecture stays put.

For anyone whose career plan runs through a mentored trial, the practical instruction is short. Use the 2027 windows. Decouple your trial funding from your career development funding. And put something on the record by September 30 — because the mechanism that replaces this one is, at the moment, still being drafted from public comment.

Tracking K award NOFOs, RFI deadlines, and the parent announcements that replace them? Granted monitors federal funding notices and surfaces the ones that match your research profile.